Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOXTheodoros Michelakos, Cristina R. Ferrone, Vikram Deshpande et al.|Annals of Surgery|2017Cited by 326
Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal AdenocarcinomaHao Liu, Kamila Naxerova, Matthias Pinter et al.|Clinical Cancer Research|2017Cited by 102
Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant TherapyTheodoros Michelakos, Cristina R. Ferrone, Lei Cai et al.|JNCI Journal of the National Cancer Institute|2020Cited by 74